

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## ATYPICALS

---

### Products Affected

#### Step 2:

- ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR
- ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
- ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG INTRAMUSCULAR
- ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 400 MG INTRAMUSCULAR
- ABILIFY MYCITE TABLET 10 MG ORAL
- ABILIFY MYCITE TABLET 15 MG ORAL
- ABILIFY MYCITE TABLET 2 MG ORAL
- ABILIFY MYCITE TABLET 20 MG ORAL
- ABILIFY MYCITE TABLET 30 MG ORAL
- ABILIFY MYCITE TABLET 5 MG ORAL
- CAPLYTA CAPSULE 42 MG ORAL
- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- INVEGA SUSTENNA SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML INTRAMUSCULAR
- INVEGA SUSTENNA SUSPENSION PREFILLED SYRINGE 156 MG/ML INTRAMUSCULAR
- INVEGA SUSTENNA SUSPENSION PREFILLED SYRINGE 234 MG/1.5ML INTRAMUSCULAR
- INVEGA SUSTENNA SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML INTRAMUSCULAR
- INVEGA SUSTENNA SUSPENSION PREFILLED SYRINGE 78 MG/0.5ML INTRAMUSCULAR
- INVEGA TRINZA SUSPENSION PREFILLED SYRINGE 273 MG/0.875ML INTRAMUSCULAR
- INVEGA TRINZA SUSPENSION PREFILLED SYRINGE 410 MG/1.315ML INTRAMUSCULAR
- INVEGA TRINZA SUSPENSION PREFILLED SYRINGE 546 MG/1.75ML INTRAMUSCULAR
- INVEGA TRINZA SUSPENSION PREFILLED SYRINGE 819 MG/2.625ML INTRAMUSCULAR
- LATUDA TABLET 120 MG ORAL
- LATUDA TABLET 20 MG ORAL
- LATUDA TABLET 40 MG ORAL
- LATUDA TABLET 60 MG ORAL
- LATUDA TABLET 80 MG ORAL
- NUPLAZID CAPSULE 34 MG ORAL
- NUPLAZID TABLET 10 MG ORAL
- PERSERIS PREFILLED SYRINGE 120 MG SUBCUTANEOUS
- PERSERIS PREFILLED SYRINGE 90 MG SUBCUTANEOUS
- REXULTI TABLET 0.25 MG ORAL
- REXULTI TABLET 0.5 MG ORAL

Y0135\_ST20\_C

Formulary ID:20157\_Version 18

Last Updated: 11/23/2020

Effective Date: 12/01/2020

## Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

- REXULTI TABLET 1 MG ORAL
- REXULTI TABLET 2 MG ORAL
- REXULTI TABLET 3 MG ORAL
- REXULTI TABLET 4 MG ORAL
- RISPERDAL CONSTA SUSPENSION RECONSTITUTED ER 12.5 MG INTRAMUSCULAR
- RISPERDAL CONSTA SUSPENSION RECONSTITUTED ER 25 MG INTRAMUSCULAR
- RISPERDAL CONSTA SUSPENSION RECONSTITUTED ER 37.5 MG INTRAMUSCULAR
- RISPERDAL CONSTA SUSPENSION RECONSTITUTED ER 50 MG INTRAMUSCULAR
- SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL
- VERSACLOZ SUSPENSION 50 MG/ML ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL
- ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR

### Details

Criteria	
	Claim will pay automatically for any brand formulary atypical antipsychotic if enrollee has a paid claim for at least a 1 day supply of any generic formulary atypical antipsychotic in the past 365 days. Otherwise, any brand formulary atypical antipsychotic requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic formulary atypical antipsychotic, (2) history of adverse event with any generic formulary atypical antipsychotic, or (3) any generic formulary atypical antipsychotic is contraindicated.

Y0135\_ST20\_C  
 Formulary ID:20157\_Version 18  
 Last Updated: 11/23/2020  
 Effective Date: 12/01/2020

**Provider Partners Maryland Advantage Plan  
2020 Formulary – Step Therapy Criteria**

## **CONDYLOX**

---

### **Products Affected**

**Step 2:**

- CONDYLOX GEL 0.5 % EXTERNAL

### **Details**

---

<b>Criteria</b>	Claim will pay automatically for Condylox if enrollee has a paid claim for at least a 1 day supply of podofilox in the past 365 days. Otherwise, Condylox requires a step therapy exception request indicating: (1) history of inadequate treatment response with podofilox OR (2) history of adverse event with podofilox OR (3) podofilox is contraindicated.
-----------------	---

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## DHE

---

### Products Affected

#### Step 2:

- *dihydroergotamine mesylate solution 4 mg/ml nasal*

### Details

---

Criteria	
	Claim will pay automatically for DHE if enrollee has a paid claim for at least a 1 day supply of any generic formulary serotonin (5-HT) 1b/1d receptor agonist (i.e. triptan) in the past 365 days. Otherwise, DHE requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic formulary triptan, OR (2) history of adverse event with any generic formulary triptan, OR (3) any generic formulary triptan is contraindicated.

---

Y0135\_ST20\_C  
Formulary ID:20157\_Version 18  
Last Updated: 11/23/2020  
Effective Date: 12/01/2020

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## DIFICID

---

### Products Affected

#### Step 2:

- DIFICID TABLET 200 MG ORAL

### Details

---

<b>Criteria</b>	Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 day supply of vancomycin or Firvanq in the past 120 days. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with vancomycin or Firvanq, OR (2) history of adverse event with vancomycin or Firvanq, OR (3) vancomycin or Firvanq is contraindicated.
-----------------	---

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## NEUPRO

---

### Products Affected

#### Step 2:

- NEUPRO PATCH 24 HOUR 1 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 2 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 3 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 4 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 8 MG/24HR TRANSDERMAL

### Details

---

<b>Criteria</b>	Claim will pay automatically for Neupro if enrollee has a paid claim for at least a 1 day supply of pramipexole or ropinirole in the past 365 days. Otherwise, Neupro requires a step therapy exception request indicating: (1) history of inadequate treatment response with pramipexole or ropinirole, OR (2) history of adverse event with pramipexole or ropinirole, OR (3) pramipexole or ropinirole is contraindicated.
-----------------	---

Y0135\_ST20\_C  
Formulary ID:20157\_Version 18  
Last Updated: 11/23/2020  
Effective Date: 12/01/2020

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## PPI

---

### Products Affected

#### Step 2:

- DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL
- DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL

### Details

---

Criteria
Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 day supply of lansoprazole, omeprazole or pantoprazole in the past 365 days. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with lansoprazole, omeprazole or pantoprazole, OR (2) history of adverse event with lansoprazole, omeprazole or pantoprazole, OR (3) lansoprazole, omeprazole or pantoprazole is contraindicated.

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## RYTARY

---

### Products Affected

#### Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

### Details

---

Criteria	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated.
----------	--

Y0135\_ST20\_C  
Formulary ID:20157\_Version 18  
Last Updated: 11/23/2020  
Effective Date: 12/01/2020



**Provider Partners Maryland Advantage Plan  
2020 Formulary – Step Therapy Criteria**

**TOPICAL ANTI-INFLAMMATORY**

---

**Products Affected**

**Step 2:**

- EUCRISA OINTMENT 2 % EXTERNAL
- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

**Details**

---

<b>Criteria</b>	Claim will pay automatically for Eucrisa, pimecrolimus or tacrolimus external if enrollee has a paid claim for at least a 1 day supply of any formulary topical corticosteroid in the past 365 days. Otherwise, Eucrisa, pimecrolimus or tacrolimus external requires a step therapy exception request indicating: (1) history of inadequate treatment response with any formulary topical corticosteroid, OR (2) history of adverse event with any formulary topical corticosteroid, OR (3) any formulary topical corticosteroid is contraindicated.
-----------------	---

---

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## UCERIS

---

### Products Affected

#### Step 2:

- *budesonide er tablet extended release 24 hour 9 mg oral*
- UCERIS FOAM 2 MG/ACT RECTAL

### Details

---

Criteria	Claim will pay automatically for Budesonide ER 9mg or Uceris Rectal Foam if enrollee has a paid claim for at least a 1 day supply of any formulary corticosteroid used to treat ulcerative colitis in the past 365 days. Otherwise, Budesonide ER 9mg or Uceris Rectal Foam requires a step therapy exception request indicating: (1) history of inadequate treatment response with any formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with any formulary corticosteroid used to treat ulcerative colitis, OR (3) any formulary corticosteroid used to treat ulcerative colitis is contraindicated.
----------	---

Y0135\_ST20\_C  
Formulary ID:20157\_Version 18  
Last Updated: 11/23/2020  
Effective Date: 12/01/2020

# Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

## ZYFLO

---

### Products Affected

#### Step 2:

- *zileuton er tablet extended release 12 hour* • ZYFLO TABLET 600 MG ORAL  
600 mg oral

### Details

---

Criteria
Claim will pay automatically for Zyflo CR or zileuton if enrollee has a paid claim for at least a 1 day supply of montelukast or zafirlukast in the past 365 days. Otherwise, Zyflo CR or zileuton require a step therapy exception request indicating: (1) history of inadequate treatment response with montelukast or zafirlukast, OR (2) history of adverse event with montelukast or zafirlukast, OR (3) montelukast or zafirlukast is contraindicated.

---

## Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

### Alphabetical Listing

#### A

ABILIFY MAINTENA PREFILLED  
SYRINGE 300 MG INTRAMUSCULAR  
..... 1, 5

ABILIFY MAINTENA PREFILLED  
SYRINGE 400 MG INTRAMUSCULAR  
..... 1, 5

ABILIFY MAINTENA SUSPENSION  
RECONSTITUTED ER 300 MG  
INTRAMUSCULAR ..... 1, 5

ABILIFY MAINTENA SUSPENSION  
RECONSTITUTED ER 400 MG  
INTRAMUSCULAR ..... 1, 5

ABILIFY MYCITE TABLET 10 MG  
ORAL..... 1, 5

ABILIFY MYCITE TABLET 15 MG  
ORAL..... 1, 5

ABILIFY MYCITE TABLET 2 MG ORAL  
..... 1, 5

ABILIFY MYCITE TABLET 20 MG  
ORAL..... 1, 5

ABILIFY MYCITE TABLET 30 MG  
ORAL..... 1, 5

ABILIFY MYCITE TABLET 5 MG ORAL  
..... 1, 5

#### B

budesonide er tablet extended release 24  
hour 9 mg oral..... 20

#### C

CAPLYTA CAPSULE 42 MG ORAL... 1, 5

CONDYLOX GEL 0.5 % EXTERNAL... 12

#### D

DEXILANT CAPSULE DELAYED  
RELEASE 30 MG ORAL..... 17

DEXILANT CAPSULE DELAYED  
RELEASE 60 MG ORAL..... 17

DIFICID TABLET 200 MG ORAL ..... 14

dihydroergotamine mesylate solution 4  
mg/ml nasal..... 13

#### E

EUCRISA OINTMENT 2 % EXTERNAL  
..... 19

#### F

FANAPT TABLET 1 MG ORAL ..... 1, 5

FANAPT TABLET 10 MG ORAL ..... 1, 5

FANAPT TABLET 12 MG ORAL ..... 1, 5

FANAPT TABLET 2 MG ORAL ..... 1, 5

FANAPT TABLET 4 MG ORAL ..... 1, 5

FANAPT TABLET 6 MG ORAL ..... 1, 5

FANAPT TABLET 8 MG ORAL ..... 1, 5

FANAPT TITRATION PACK TABLET 1  
& 2 & 4 & 6 MG ORAL..... 1, 5

#### I

INVEGA SUSTENNA SUSPENSION  
PREFILLED SYRINGE 117  
MG/0.75ML INTRAMUSCULAR .... 1, 5

INVEGA SUSTENNA SUSPENSION  
PREFILLED SYRINGE 156 MG/ML  
INTRAMUSCULAR ..... 1, 5

INVEGA SUSTENNA SUSPENSION  
PREFILLED SYRINGE 234 MG/1.5ML  
INTRAMUSCULAR ..... 1, 5

INVEGA SUSTENNA SUSPENSION  
PREFILLED SYRINGE 39 MG/0.25ML  
INTRAMUSCULAR ..... 1, 5

INVEGA SUSTENNA SUSPENSION  
PREFILLED SYRINGE 78 MG/0.5ML  
INTRAMUSCULAR ..... 2, 5

INVEGA TRINZA SUSPENSION  
PREFILLED SYRINGE 273  
MG/0.875ML INTRAMUSCULAR... 2, 5

INVEGA TRINZA SUSPENSION  
PREFILLED SYRINGE 410  
MG/1.315ML INTRAMUSCULAR... 2, 5

INVEGA TRINZA SUSPENSION  
PREFILLED SYRINGE 546  
MG/1.75ML INTRAMUSCULAR .... 2, 5

INVEGA TRINZA SUSPENSION  
PREFILLED SYRINGE 819  
MG/2.625ML INTRAMUSCULAR... 2, 5

#### L

LATUDA TABLET 120 MG ORAL ..... 2, 5

LATUDA TABLET 20 MG ORAL ..... 2, 5

LATUDA TABLET 40 MG ORAL ..... 2, 5

## Provider Partners Maryland Advantage Plan 2020 Formulary – Step Therapy Criteria

LATUDA TABLET 60 MG ORAL .....	2, 5	RYTARY CAPSULE EXTENDED	
LATUDA TABLET 80 MG ORAL .....	2, 5	RELEASE 23.75-95 MG ORAL .....	18
<b>N</b>		RYTARY CAPSULE EXTENDED	
NEUPRO PATCH 24 HOUR 1 MG/24HR		RELEASE 36.25-145 MG ORAL .....	18
TRANSDERMAL.....	15, 16	RYTARY CAPSULE EXTENDED	
NEUPRO PATCH 24 HOUR 2 MG/24HR		RELEASE 48.75-195 MG ORAL .....	18
TRANSDERMAL.....	15, 16	RYTARY CAPSULE EXTENDED	
NEUPRO PATCH 24 HOUR 3 MG/24HR		RELEASE 61.25-245 MG ORAL .....	18
TRANSDERMAL.....	15, 16	<b>S</b>	
NEUPRO PATCH 24 HOUR 4 MG/24HR		SAPHRIS TABLET SUBLINGUAL 10 MG	
TRANSDERMAL.....	15, 16	SUBLINGUAL .....	3, 5
NEUPRO PATCH 24 HOUR 6 MG/24HR		SAPHRIS TABLET SUBLINGUAL 2.5	
TRANSDERMAL.....	15, 16	MG SUBLINGUAL.....	3, 5
NEUPRO PATCH 24 HOUR 8 MG/24HR		SAPHRIS TABLET SUBLINGUAL 5 MG	
TRANSDERMAL.....	15, 16	SUBLINGUAL .....	3, 5
NUPLAZID CAPSULE 34 MG ORAL .	2, 5	SECUADO PATCH 24 HOUR 3.8	
NUPLAZID TABLET 10 MG ORAL ....	2, 5	MG/24HR TRANSDERMAL .....	3, 5
<b>P</b>		SECUADO PATCH 24 HOUR 5.7	
PERSERIS PREFILLED SYRINGE 120		MG/24HR TRANSDERMAL .....	3, 5
MG SUBCUTANEOUS .....	2, 5	SECUADO PATCH 24 HOUR 7.6	
PERSERIS PREFILLED SYRINGE 90 MG		MG/24HR TRANSDERMAL .....	3, 5
SUBCUTANEOUS.....	2, 5	<b>T</b>	
pimecrolimus cream 1 % external.....	19	tacrolimus ointment 0.03 % external .....	19
<b>R</b>		tacrolimus ointment 0.1 % external .....	19
REXULTI TABLET 0.25 MG ORAL ....	2, 5	<b>U</b>	
REXULTI TABLET 0.5 MG ORAL .....	2, 5	UCERIS FOAM 2 MG/ACT RECTAL ....	20
REXULTI TABLET 1 MG ORAL .....	2, 5	<b>V</b>	
REXULTI TABLET 2 MG ORAL .....	2, 5	VERSACLOZ SUSPENSION 50 MG/ML	
REXULTI TABLET 3 MG ORAL .....	2, 5	ORAL.....	3, 5
REXULTI TABLET 4 MG ORAL .....	2, 5	VRAYLAR CAPSULE 1.5 MG ORAL .	3, 5
RISPERDAL CONSTA SUSPENSION		VRAYLAR CAPSULE 3 MG ORAL ....	3, 5
RECONSTITUTED ER 12.5 MG		VRAYLAR CAPSULE 4.5 MG ORAL .	3, 5
INTRAMUSCULAR .....	2, 5	VRAYLAR CAPSULE 6 MG ORAL ....	3, 5
RISPERDAL CONSTA SUSPENSION		VRAYLAR CAPSULE THERAPY PACK	
RECONSTITUTED ER 25 MG		1.5 & 3 MG ORAL .....	3, 5
INTRAMUSCULAR .....	2, 5	<b>Z</b>	
RISPERDAL CONSTA SUSPENSION		zileuton er tablet extended release 12 hour	
RECONSTITUTED ER 37.5 MG		600 mg oral .....	21
INTRAMUSCULAR .....	2, 5	ZYFLO TABLET 600 MG ORAL .....	21
RISPERDAL CONSTA SUSPENSION		ZYPREXA RELPREVV SUSPENSION	
RECONSTITUTED ER 50 MG		RECONSTITUTED 210 MG	
INTRAMUSCULAR .....	2, 5	INTRAMUSCULAR .....	3, 5